When to treat patients with relapsed follicular lymphoma

Chan Yoon Cheah, John F. Seymour

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)


Introduction: Follicular lymphoma is the most common indolent lymphoma and remains incurable for the majority of patients despite recent major advances. The disease is typically initially chemosensitive, however relapse is inevitable. In contrast to the frontline setting, studies addressing the optimal timing of initiating second line therapy have not been performed and subsequently practice varies considerably. Areas covered: In the review, we consider the available literature regarding timing of therapy in patients with follicular lymphoma and consider key insights from FL biology to provide guidance on when to treat patients with relapsed disease. Expert commentary: We recommend re-biopsy at time of relapse, immediate treatment of patients with histologic transformation. Treatment for those with recurrent follicular lymphoma may be safely delayed in the absence of bulk, compressive or constitutional symptoms, cytopenias related to lymphoma or steady progression. Patients with localized relapse may be considered for radiotherapy if the involved field would result in minimal toxicity.

Original languageEnglish
Pages (from-to)187-191
Number of pages5
JournalExpert Review of Hematology
Issue number3
Publication statusPublished - 4 Mar 2017


Dive into the research topics of 'When to treat patients with relapsed follicular lymphoma'. Together they form a unique fingerprint.

Cite this